Why Where Fat Sits Matters More Than the Scale

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

In Brief

Not all body fat carries the same cardiovascular risk. Fat stored deep in the abdomen and inside organs is more strongly linked to insulin resistance, abnormal cholesterol, high blood pressure, and inflammation than fat stored under the skin, particularly on the hips and thighs. This helps explain why two people at the same weight can have very different cardiometabolic risk — and why the scale alone can mislead. Waist measurement offers a simple window into central fat, but it has limits: it helps assess adiposity and follow change over time, while a fuller cardiovascular assessment still depends on blood pressure, glucose, lipids, fitness, and existing health conditions.

The Same Weight, Two Different Risks

Picture two people of the same height who weigh exactly the same. One carries much of that weight on the hips and thighs and has little fat inside the abdomen. The other carries it around the middle, with fat packed deep among the organs and seeping into the liver. On the scale, and often on a body mass index chart, they look identical. Biologically, they are not — and their cardiovascular risk can differ substantially.

The reason is that fat is not one tissue in one place. The body stores it in distinct depots that behave very differently. Fat under the skin is a relatively safer reservoir. Fat deep in the abdomen — visceral fat — is metabolically active in harmful ways. And when that storage capacity is exceeded or becomes dysfunctional, excess lipid can accumulate in places it does not belong, including the liver, muscle, pancreas, and the tissue surrounding the heart. These harmful depots — visceral and ectopic fat — carry cardiovascular risk that total body weight alone does not capture. Visceral fat, accurately measured by CT or MRI, is an independent marker of cardiovascular and metabolic disease and of death — meaning it carries risk beyond what overall body size explains.¹

This is the single most important refinement of the message from Article 1, which established that weight harms the heart through what fat does rather than through weight itself. Where fat sits is a large part of what determines what it does. This article covers the fat depots and how they differ, why visceral and ectopic fat are so damaging, why individuals diverge at the same weight, how sex and ethnicity shape fat storage, and what the waistline genuinely reveals. It is the second of eleven articles; Article 3 turns to how all of this is actually measured.

Where the Body Stores Fat — and Why It Matters

Body fat sits in three broad compartments, and the differences between them are the whole story.

Subcutaneous fat lies just under the skin. It is the fat you can pinch, and it is where the body is designed to store surplus energy. Stored here — particularly on the hips, thighs, and buttocks — fat is relatively inert and carries comparatively low cardiometabolic risk.¹,² This is the relatively safer depot: expandable, out of the way of the organs, and not, on its own, a major driver of heart disease.

Visceral fat sits deep inside the abdomen, wrapped around the liver, intestines, and other organs. It cannot be pinched, and a person can carry a large amount of it while looking only moderately overweight. Unlike subcutaneous fat, visceral fat is metabolically active in ways that harm the cardiovascular system, which is why it is measured and tracked as an independent risk marker.¹,²

Ectopic fat is fat stored where it does not belong — inside organs and tissues rather than in fat depots. This includes fat in the liver, in and around muscle, in the pancreas, and in the tissue surrounding the heart. Ectopic fat tends to accumulate when subcutaneous storage capacity is exceeded or becomes dysfunctional, and emerging evidence links it — particularly liver fat and fat around the heart — to atherosclerosis and cardiometabolic risk.¹

The table below summarizes the three depots. The distinction it draws — relatively safer storage versus more harmful storage — is the concept the rest of this article builds on.

Where Fat Is Stored, and How It Behaves

The key idea is not that some fat is “good.” It is that the body has a limited capacity for safer storage, and much of the harm begins when fat is forced into compartments not built to hold it.

Why Visceral Fat Is So Harmful

Visceral fat is dangerous not because of where it sits but because of what it does from there — and one anatomical feature helps explain part of it. The veins draining visceral fat empty directly into the portal vein, the blood vessel that carries blood from the gut straight to the liver. Whatever visceral fat releases therefore arrives at the liver first and in high concentration.²

What it releases is the problem. Visceral fat is more lipolytically active than subcutaneous fat, meaning it breaks down and releases free fatty acids more readily. Delivered to the liver in excess, those fatty acids drive several linked changes. The liver becomes resistant to insulin, produces more glucose, and manufactures more triglyceride-rich particles. The cholesterol profile shifts toward higher triglycerides, lower HDL cholesterol, and an increased burden of atherogenic ApoB-containing particles, often including smaller, denser LDL particles.²,¹² Portal delivery is only part of the story, though. Dysfunctional visceral fat also releases more pro-inflammatory signals and less of the protective, insulin-sensitizing hormone adiponectin, affecting the circulation more broadly. The result is the familiar cluster: insulin resistance, atherogenic cholesterol, higher blood pressure, and low-grade inflammation — the same cardiometabolic cascade described in Article 1, now traced to a specific fat depot.²

This is why visceral fat is measured and studied as an independent risk marker rather than a cosmetic concern. Across studies spanning three decades, greater visceral fat has been associated with more cardiovascular and metabolic disease and higher mortality, over and above what total body weight predicts.¹ The mechanisms it feeds — the same ones that raise blood sugar, distort cholesterol, and injure blood vessels — are covered in depth across the Diabetes, Cholesterol, and Hypertension series.

Ectopic Fat: When Fat Ends Up Where It Doesn’t Belong

When subcutaneous storage capacity is exceeded or becomes dysfunctional, excess lipid can increasingly accumulate in organs and tissues not designed for long-term fat storage. This ectopic fat is a newer and still-developing area of cardiovascular science, and the evidence is best described as emerging rather than settled — but it helps explain risk that visceral fat alone does not.

Liver fat is the most studied. When triglycerides accumulate in liver cells, the result is metabolic-dysfunction-associated fatty liver — closely tied to insulin resistance and an atherogenic cholesterol profile. Emerging evidence associates excess liver fat with atherosclerosis and cardiometabolic risk, though the extent to which liver fat causes cardiovascular events, as opposed to marking the metabolic state that does, is still being worked out.¹

Fat around the heart — epicardial and pericardial fat, sitting directly against the heart muscle and the coronary arteries — has drawn particular attention. Because it is in direct contact with the heart and the vessels feeding it, this fat may exert local effects, and emerging evidence links it to atherosclerosis and to atrial fibrillation, the common irregular heart rhythm.¹ The American Heart Association’s scientific statement recognizes obesity as a contributor to atrial fibrillation and to heart failure, and fat surrounding and infiltrating the heart is one proposed mechanism.⁷ These connections are examined in the Arrhythmia and Heart Failure series.

The practical point is not that a person needs to know their liver-fat percentage. It is that the same overflow model — storage capacity exceeded, lipid accumulating in organs — links a “normal” scale weight to real cardiovascular risk, and explains why the number on the scale can be so misleading.

The Personal Fat Threshold: Why Two People at the Same Weight Differ

Given that where fat sits shapes risk beyond total weight, the next question is what decides where a person’s fat goes. Much of the answer is the capacity of their relatively safer subcutaneous storage — and that capacity varies widely from person to person.

One useful framework is the personal fat threshold: the idea that individuals differ substantially in how much fat they can accumulate before ectopic fat and metabolic dysfunction emerge — a limit crossed at very different body weights in different people.⁸ It is a conceptual model rather than a number anyone can measure for an individual, but it captures something real. Someone with a high threshold can carry considerable weight before fat spills into the liver and viscera, and may remain metabolically healthy at a high BMI, at least for a time. Someone with a low threshold can exceed it while still appearing slim, developing insulin resistance and even type 2 diabetes at a “normal” weight. This framework was proposed to explain a long-standing puzzle: why a meaningful share of people who develop type 2 diabetes are not overweight by BMI, and why weight loss can restore normal blood sugar even in people who were never obese.⁸

This is the biology beneath the phrase “thin outside, fat inside.” A person can have an unremarkable BMI and a normal waistline to the eye, yet carry excess fat in the liver and around the organs. The scale and even the mirror miss it. It is also why the metabolically healthy obesity discussed in Article 1 exists, and why it is often unstable: that storage capacity can be outstripped over time, and when it is, the metabolic picture changes.

The framework also carries a hopeful implication. Within it, a modest weight loss may be enough in some people to reduce ectopic fat and substantially improve glucose metabolism.⁸

Sex and Ethnicity Shape Where Fat Goes

Where the body preferentially stores fat is not the same for everyone, and two factors matter enough to name.

Sex is one. On average, men store more fat viscerally, in the abdomen — the “apple” pattern — while women before menopause store proportionally more under the skin on the hips and thighs — the “pear” pattern — which is metabolically safer. Sex hormones contribute to this difference, and the pattern shifts after menopause, when fat distribution tends to become more central.² This is one reason cardiometabolic risk often rises for women in the years around menopause, a shift explored further in the Women and Cardiovascular Health series.

Population background is the second. Ancestry and ethnicity affect how BMI relates to cardiometabolic risk, reflecting differences in body composition, fat-storage biology, and environment. At the same BMI, South Asian adults tend to carry more visceral and liver fat and less subcutaneous fat than white Europeans — a difference measured directly with imaging — so cardiometabolic risk appears at a lower weight.¹¹ The scale of this is striking: in a large English cohort, the type 2 diabetes risk that White populations reach at a BMI of 30 was reached by South Asian populations at a BMI of just 23.9 — within the range conventionally called “normal.” The risk-equivalent thresholds were also lower for Black (28.1), Chinese (26.9), and Arab (26.6) populations.⁹ This is why major guidelines now apply lower BMI and waist thresholds for several ethnic groups rather than a single universal cutoff.³

Neither of these is a reason for fatalism. They are reasons to interpret the same numbers differently for different people — and, as the next section shows, to lean on a measure that partly sidesteps the problem.

What the Waistline Tells You — and What It Doesn’t

Because visceral fat is concentrated in the abdomen, the simplest window into it is the waist. Waist circumference and the related waist-to-hip ratio consistently capture cardiovascular risk that BMI alone misses — but the honest account of what they add has two halves, and both matter.

On one side, abdominal fat is a genuine, independent risk marker. In the INTERHEART study of roughly 27,000 people across 52 countries, waist-to-hip ratio showed a graded, strong association with heart attack worldwide, while BMI was only weakly related once other factors were accounted for.⁶ In the large EPIC study of over 350,000 European adults, those with the largest waists had roughly 1.8 to 2 times the risk of death of those with the smallest, even after accounting for BMI.⁴ Because these are observational studies, they establish association rather than proof of cause; but the pattern is consistent and large. On the strength of evidence like this, an international consensus recommends that waist circumference be treated as a vital sign — measured routinely alongside BMI, because BMI alone is not sufficient to assess the risk of increased adiposity — and that reducing waist size be treated as a genuine treatment target.³

On the other side is a limit worth stating plainly, because it is often overlooked. Once a person’s blood pressure, cholesterol, and blood sugar have actually been measured, the waistline adds little to formal cardiovascular risk prediction. In a collaborative analysis of 58 prospective studies, adding BMI, waist circumference, or waist-to-hip ratio to a risk model that already included blood pressure, diabetes, and lipids did not meaningfully improve the prediction of cardiovascular events.⁵ The three adiposity measures had broadly similar associations with coronary disease, and none stood out.⁵ This is not a contradiction. Waist circumference and formal cardiovascular risk prediction answer related but different questions: the waist helps identify central adiposity, while risk models incorporate downstream factors such as blood pressure, diabetes status, and lipids that already capture substantial information about cardiovascular risk.

Put together, the message is practical. The waist is genuinely useful for spotting and following central adiposity, and reducing it is a legitimate goal — but it is one input into cardiovascular risk, not a stand-alone risk score.³

Measuring the Waist

One measurement makes this practical, and it can be done at home with a tape measure using a consistent technique — Article 3 sets out the method in detail. Using the same method each time is what makes the trend over months meaningful.³

A simple companion is the waist-to-height ratio. A practical rule used in NICE guidance is to keep the waist below half of one’s height — a waist-to-height ratio under 0.5. NICE notes this can be applied across ethnic groups and both sexes, and measured by a person at home.¹⁰ It is a screening prompt rather than a diagnosis or a treatment target: a reading over the boundary is a reason to look further. A waistline that decreases over time generally reflects a fall in central abdominal fat — a favorable direction — even though a tape measure cannot separate visceral from subcutaneous fat. How the waist fits together with blood pressure, cholesterol, blood sugar, body composition, and fitness into a fuller assessment is the subject of Article 3.

Clinical Bottom Line

Where fat is stored can matter as much as — and sometimes more than — the number on the scale, because visceral and ectopic fat carry risks that BMI alone cannot see.¹ Fat under the skin, especially on the lower body, is relatively safer storage; visceral fat (packed around the abdominal organs) and ectopic fat (inside organs such as the liver and around the heart) are closely linked to the insulin resistance, atherogenic lipid patterns, higher blood pressure, and inflammatory pathways that contribute to cardiovascular disease.¹,² Because people differ substantially in fat distribution and in how much adiposity they can accumulate before metabolic dysfunction emerges, two people at the same weight can carry very different risk — and a person of “normal” weight can be at real cardiometabolic risk while some people at a higher weight are not.⁸ Waist size is a useful, low-cost window into central fat that the scale misses, and reducing it is a legitimate goal;³ its honest limit is that, once blood pressure, cholesterol, and blood sugar are known, it adds little to formal risk prediction.⁵ The practical takeaway: pay attention to the middle, use the waist-below-half-your-height rule as a simple screening guide, and treat a sustained downward trend in excess central adiposity as meaningful progress — not a demand for a perfect number.

What Comes Next

This article established that where fat is stored — not weight alone — shapes cardiovascular risk, and that the waistline is a useful but bounded window into it. Article 3 takes the next step: how cardiometabolic health is actually measured, why BMI misleads in both directions, and how waist, body composition, blood pressure, lipids, and glucose fit together into a truer picture than any single number can provide.

Key Terms

Subcutaneous fat: Fat stored just under the skin, especially on the hips, thighs, and buttocks; the body’s relatively safer, designed energy store, carrying comparatively low cardiometabolic risk.

Visceral fat: Fat stored deep in the abdomen, around the internal organs; metabolically active and an independent marker of cardiovascular and metabolic disease, because it drains to the liver and releases fatty acids and inflammatory signals.

Ectopic fat: Fat stored inside organs and tissues — the liver, muscle, pancreas, and around the heart — rather than in fat depots; tends to accumulate when subcutaneous storage capacity is exceeded or becomes dysfunctional.

Portal vein: The blood vessel carrying blood from the gut and visceral fat directly to the liver, which is why substances released by visceral fat reach the liver first and in high concentration.

Free fatty acids: Fat molecules released into the bloodstream when fat tissue breaks down; delivered to the liver in excess, they promote insulin resistance and abnormal cholesterol production.

Personal fat threshold: A conceptual framework holding that individuals differ in how much fat they can accumulate before ectopic fat and metabolic dysfunction emerge; the threshold is crossed at different body weights in different people and is not a number that can be measured for an individual.

Waist circumference: The distance around the abdomen; a simple, low-cost measure of central (abdominal) fat that captures cardiovascular risk not reflected by BMI.

Waist-to-height ratio (WHtR): Waist circumference divided by height; a value under 0.5 (“waist less than half your height”) is used in NICE guidance as a screening marker of central fat across sexes and ethnic groups.

Waist-to-hip ratio: Waist circumference divided by hip circumference; another marker of abdominal fat distribution associated with cardiovascular risk and mortality.

Epicardial and pericardial fat: Fat located directly against the heart muscle and coronary arteries (epicardial) and within the sac surrounding the heart (pericardial); studied as possible local contributors to atherosclerosis and atrial fibrillation.

References

1. Neeland IJ, Ross R, Després JP, et al; International Atherosclerosis Society; International Chair on Cardiometabolic Risk Working Group on Visceral Obesity. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715–725. https://doi.org/10.1016/S2213-8587(19)30084-1
2. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359–404. https://doi.org/10.1152/physrev.00033.2011
3. Ross R, Neeland IJ, Yamashita S, et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat Rev Endocrinol. 2020;16(3):177–189. https://doi.org/10.1038/s41574-019-0310-7
4. Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008;359(20):2105–2120. https://doi.org/10.1056/NEJMoa0801891
5. Emerging Risk Factors Collaboration; Wormser D, Kaptoge S, Di Angelantonio E, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377(9771):1085–1095. https://doi.org/10.1016/S0140-6736(11)60105-0
6. Yusuf S, Hawken S, Ôunpuu S, et al; INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366(9497):1640–1649. https://doi.org/10.1016/S0140-6736(05)67663-5
7. Powell-Wiley TM, Poirier P, Burke LE, et al; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21):e984–e1010. https://doi.org/10.1161/CIR.0000000000000973
8. Taylor R, Holman RR. Normal weight individuals who develop type 2 diabetes: the personal fat threshold. Clin Sci (Lond). 2015;128(7):405–410. https://doi.org/10.1042/CS20140553
9. Caleyachetty R, Barber TM, Mohammed NI, et al. Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2021;9(7):419–426. https://doi.org/10.1016/S2213-8587(21)00088-7
10. National Institute for Health and Care Excellence (NICE). Overweight and obesity management. NICE guideline NG246. London: NICE; 2025. https://www.nice.org.uk/guidance/ng246
11. Anand SS, Tarnopolsky MA, Rashid S, et al. Adipocyte hypertrophy, fatty liver and metabolic risk factors in South Asians: the Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE). PLoS One. 2011;6(7):e22112. https://doi.org/10.1371/journal.pone.0022112
12. Bays HE, Kirkpatrick CF, Maki KC, et al. Obesity, dyslipidemia, and cardiovascular disease: a joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. J Clin Lipidol. 2024;18(3):e320–e350. https://doi.org/10.1016/j.jacl.2024.04.001

HeartBuddi • Your heart. Own it.